From bench to bedside: 64Cu/177Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications

EJNMMI Research

Table 6 Cumulated therapeutic activity to reach AD safety and efficacy levels

Target Organ (AD limit) [36]	Cumulated administered activity (GBq) to reach AD safety limit or AD efficacy threshold (in tumor)
	M1		M2		M3		M4
	1 DOTA	3 DOTA	1 DOTA	3 DOTA	1 DOTA	3 DOTA	1 DOTA	3 DOTA
Heart wall (30 Gy) [27]	80.4	129.3	82.4	204.1	33.6	51.8	50.7	87.0
Kidneys (30 Gy) [29]	27.5	45.8	100.3	161.3	20.3	23.4	74.1	88.0
Liver (40 Gy) [28]	30.8	22.3	78.3	58.7	31.5	22.3	79.8	57.0
Lungs (20 Gy) [27]	186.9	255.4	107.5	125.0	90.1	116.3	49.4	56.8
Red Marrow (2 Gy) [31]	10.5	10.8	5.7	9.6	9.4	5.4	4.7	5.2
Uterus (16 Gy) [30]	5.1	8.5	23.4	25.0	5.1	24.9	21.9	140.4
Total Body (4 Gy) [32]	25.5	28.8	25.5	28.8	25.5	28.8	25.5	28.8
Tumor STS (60 Gy) [33]	32.7	41.1

The table reports the cumulated therapeutic administered activity required to reach limiting-organ AD safety limits and the efficacy AD thresholds of 60 Gy in STS for the [¹⁷⁷Lu]Lu-1C1m-Fc 1 DOTA and 3 DOTA as a function of the mice-to-human dosimetry extrapolation method (M1-M4)